中国医学前沿杂志（电子版）
中國醫學前沿雜誌（電子版）
중국의학전연잡지（전자판）
Chinese Journal of the Frontiers of Medical Science (Electronic Version)
2015年
9期
29-32
,共4页
马丽芬%刘彦君%苏振丽%郑瑜
馬麗芬%劉彥君%囌振麗%鄭瑜
마려분%류언군%소진려%정유
厄贝沙坦%高压氧%2型糖尿病%微血管病变
阨貝沙坦%高壓氧%2型糖尿病%微血管病變
액패사탄%고압양%2형당뇨병%미혈관병변
Irbesartan%Hyperbaric oxygen%Type 2 diabetes mellitus%Microangiopathy
目的：探讨高压氧联合厄贝沙坦预防2型糖尿病患者微血管病变的临床效果。方法选取本院2009年4月至2011年4月诊断为2型糖尿病患者120例为研究对象，采用区组随机方法分为对照组和观察组。对照组患者给予高压氧干预，1次/天，10天为一疗程，连续3个疗程；观察组患者在对照组基础上口服厄贝沙坦，150 mg/次，1次/天，10天为一疗程，连续服用3个疗程。两组患者均给予同等降糖药物治疗。随访3年，观察比较两组患者微血管病变及血糖情况。结果随时间延长，两组患者空腹血糖（FPG）、餐后2小时血糖（2hPG）、糖化血红蛋白（HbA1c）水平逐渐下降，且观察组下降趋势更明显（P＜0.05）；观察组患者尿微量清蛋白排泄率（urinary albumin excreting rate， UAER）基本处于平稳状态，对照组患者UAER上升速度明显快于观察组（P＜0.05）；对照组患者踝-肱指数（ankle-brachial index，ABI）下降速度快于观察组（P＜0.05）；观察组患者出现1例Ⅰ期和1例Ⅱ期视网膜病变，对照组患者出现5例Ⅰ期、3例Ⅱ期和1例Ⅲ期视网膜病变（χ2＝4.90，P＜0.05）。结论高压氧联合厄贝沙坦能够更好地预防2型糖尿病患者微血管病变的发生。
目的：探討高壓氧聯閤阨貝沙坦預防2型糖尿病患者微血管病變的臨床效果。方法選取本院2009年4月至2011年4月診斷為2型糖尿病患者120例為研究對象，採用區組隨機方法分為對照組和觀察組。對照組患者給予高壓氧榦預，1次/天，10天為一療程，連續3箇療程；觀察組患者在對照組基礎上口服阨貝沙坦，150 mg/次，1次/天，10天為一療程，連續服用3箇療程。兩組患者均給予同等降糖藥物治療。隨訪3年，觀察比較兩組患者微血管病變及血糖情況。結果隨時間延長，兩組患者空腹血糖（FPG）、餐後2小時血糖（2hPG）、糖化血紅蛋白（HbA1c）水平逐漸下降，且觀察組下降趨勢更明顯（P＜0.05）；觀察組患者尿微量清蛋白排洩率（urinary albumin excreting rate， UAER）基本處于平穩狀態，對照組患者UAER上升速度明顯快于觀察組（P＜0.05）；對照組患者踝-肱指數（ankle-brachial index，ABI）下降速度快于觀察組（P＜0.05）；觀察組患者齣現1例Ⅰ期和1例Ⅱ期視網膜病變，對照組患者齣現5例Ⅰ期、3例Ⅱ期和1例Ⅲ期視網膜病變（χ2＝4.90，P＜0.05）。結論高壓氧聯閤阨貝沙坦能夠更好地預防2型糖尿病患者微血管病變的髮生。
목적：탐토고압양연합액패사탄예방2형당뇨병환자미혈관병변적림상효과。방법선취본원2009년4월지2011년4월진단위2형당뇨병환자120례위연구대상，채용구조수궤방법분위대조조화관찰조。대조조환자급여고압양간예，1차/천，10천위일료정，련속3개료정；관찰조환자재대조조기출상구복액패사탄，150 mg/차，1차/천，10천위일료정，련속복용3개료정。량조환자균급여동등강당약물치료。수방3년，관찰비교량조환자미혈관병변급혈당정황。결과수시간연장，량조환자공복혈당（FPG）、찬후2소시혈당（2hPG）、당화혈홍단백（HbA1c）수평축점하강，차관찰조하강추세경명현（P＜0.05）；관찰조환자뇨미량청단백배설솔（urinary albumin excreting rate， UAER）기본처우평은상태，대조조환자UAER상승속도명현쾌우관찰조（P＜0.05）；대조조환자과-굉지수（ankle-brachial index，ABI）하강속도쾌우관찰조（P＜0.05）；관찰조환자출현1례Ⅰ기화1례Ⅱ기시망막병변，대조조환자출현5례Ⅰ기、3례Ⅱ기화1례Ⅲ기시망막병변（χ2＝4.90，P＜0.05）。결론고압양연합액패사탄능구경호지예방2형당뇨병환자미혈관병변적발생。
ObjectiveTo explore the clinical effect of hyperbaric oxygen combined with irbesartan in prevention of type 2 diabetes mellitus with microangiopathy.MethodSelected 120 patients diagnosed type 2 diabetic mellitus in our hospital from April 2009 to April 2011 as research objects, they were randomly divided into control group and observation group. Patients in control group were treated with hyperbaric oxygen intervention, once a day, 10 days for a course of treatment, completed 3 course. Patients in observation group were given irbesartan orally on the basis of control group, 150 mg/times, 1 times/day, 10 days for a course of treatment, completed 3 courses, also the two groups were given equal antidiabetic drug treatment. Followed up for 3 years, microangiopathy and blood glucose were compared between the two groups.ResultFPG, HbA1c, 2hPG levels of the two groups gradually decreased, and the downward trend of observation group was more obvious (P<0.05); UAER of observation group was basically in a stable state, UAER of control group increased faster than observation group (P<0.05); ABI of control group decreased faster than observation group (P<0.05); in observation group, there were 1 case of stageⅠ and 1 case of stageⅡ retinopathy, and in control group, there were 5 cases of stageⅠ, 3 cases of stageⅡand 1 case of stageⅢ retinopathy (χ2=4.90,P<0.05).ConclusionHyperbaric oxygen combined with irbesartan can better prevent occurrence of type 2 diabetic patients with microangiopathy.
